BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: It is proposed that this interaction stabilizes Bcl-2’s anti-apoptotic activity through promotion of the pro-oxidant intracellular milieu since transient transfection of the dominant negative mutant Rac1N17 resulted in a decrease in O2− levels and an increase in the sensitivity of Bcl-2-overexpressing chronic myeloid leukemia (CEM) cells to receptor or drug-induced apoptosis (Clement et al., 2003).